2020 年第 10 期 第 15 卷

荷丹片联合阿托伐他汀对血脂异常患者血清同型半胱氨酸和炎症因子水平及血管内皮舒张功能的影响

Effects of Hedan tablet combined with atorvastatin on serum homocysteine, inflammatory factors and vascular endothelial dilation function in patients with dyslipidemia

作者：罗海1张婷1王振国2

英文作者：Luo Hai1 Zhang Ting1 Wang Zhenguo2

单位：1中国人民武装警察部队特色医学中心急诊医学科，天津300162；2中国人民武装警察部队特色医学中心医研部，天津300162

英文单位：1Department of Emergency Medicine Characteristic Medical Center of Chinese People′s Armed Police Force Tianjin 300162 China; 2Department of Medical Research Characteristic Medical Center of Chinese People′s Armed Police Force Tianjin 300162 China

关键词：血脂异常；荷丹片；阿托伐他汀；同型半胱氨酸；血管内皮舒张功能

英文关键词：Dyslipidemia;Hedantablet;Atorvastatin;Homocysteine;Vascularendothelialdilationfunction

• 摘要：

• 目的 探讨荷丹片联合阿托伐他汀对血脂异常患者血清同型半胱氨酸（Hcy）、炎症因子水平及血管内皮舒张功能的影响。方法 选取2019年1—12月在中国人民武装警察部队特色医学中心就诊的90例原发性血脂异常患者为研究对象，按照随机数字表法分为对照组和观察组，各45例。对照组口服阿托伐他汀钙片10 mg，每晚1次；观察组在对照组基础上口服荷丹片1.46 g，3次/d，2组均治疗8周。观察2组治疗前后血脂、Hcy、C反应蛋白（CRP）和肿瘤坏死因子α（TNF-α）水平，肱动脉内皮依赖性舒张功能（EDD）和内皮非依赖性舒张功能（EID）变化及疗效。结果 治疗8周后，2组总胆固醇、三酰甘油、LDL-C、HDL-C水平均较治疗前改善，且观察组总胆固醇、三酰甘油水平低于对照组［（4.42±0.28）mmol/L比（4.86±0.29）mmol/L、（1.24±0.09）mmol/L比（1.36±0.08）mmol/L］，HDL-C水平高于对照组［（1.28±0.08）mmol/L比（1.16±0.08）mmol/L］（均P＜0.05）。治疗后2组CRP、TNF-α、Hcy水平均较治疗前下降，且观察组均低于对照组（均P＜0.05）。治疗后2组EDD值均较治疗前增大，且观察组高于对照组（均P＜0.05）；治疗后2组EID值与治疗前比较，差异均无统计学意义（均P＞0.05）。观察组总有效率高于对照组［95.6%（43/45）比80.0%（36/45）］（P=0.024）。结论 荷丹片联合阿托伐他汀可更好地改善血脂异常患者的血脂水平,降低血清Hcy、炎症因子水平，改善血管EDD。

• Objective To investigate the effects of Hedan tablet combined with atorvastatin on serum homocysteine (Hcy), inflammatory factors and vascular endothelial dilation function in patients with dyslipidemia. Methods From January to December 2019, 90 patients with primary dyslipidemia admitted to the Characteristic Medical Center of Chinese People′s Armed Police Force were randomly divided into the control group and observation group, with 45 cases in each group. The control group was treated with atorvastatin 10 mg, once a night; the observation group was treated with Hedan 1.46 g, three times a day on the basis of control group; both groups were treated for 8 weeks. The changes of blood lipid, Hcy, C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), endothelium-dependent diastolic (EDD) and endothelium-independent diastolic (EID) were observed before and after treatment. Results After 8 weeks of treatment, the levels of total cholesterol, triglyceride, low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) in both groups were improved; the levels of total cholesterol and triglyceride in observation group were lower than those in control group［（4.42±0.28）mmol/L vs （4.86±0.29）mmol/L,（1.24±0.09）mmol/L vs （1.36±0.08）mmol/L］; the level of HDL-C was higher than that in control group［（1.28±0.08）mmol/L vs （1.16±0.08）mmol/L］（all P＜0.05）. After treatment, the levels of CRP, TNF-α and Hcy in both groups were lower than those before treatment; the levels in observation group were lower than those in control group (all P＜0.05). After treatment, the EDD value of the two groups increased; the value in observation group was higher than that in control group (all P＜0.05). There was no significant difference of EID between before and after treatment for two groups (both P>0.05). The total effective rate in the observation group was higher than that in the control group ［95.6%（43/45） vs 80.0%（36/45）］（P=0.024）. Conclusion Hodan tablets combined with atorvastatin can better improve blood lipid levels, reduce serum Hcy and inflammatory factor levels, and improve vascular EDD in patients with dyslipidemia.